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Background: It is expected that in 2020 more than 17,000 cases of colorectal cancer will be diagnosed in The
Netherlands. To date, patients are included in a surgeon-led follow-up programme whose main focus is recurrence
detection. However, patients often experience multiple physical and psychosocial problems. Currently, these
problems are not always encountered. More care by a generalist is suggested as a solution. Furthermore, patients
prefer to undergo rehabilitation in their own environment and to be more involved in their own health care.
eHealth applications might enhance this. Oncokompas2.0 is an online self-management application which facilitates
access to supportive care. This study aims to evaluate primary care follow-up and aftercare in comparison with
secondary care follow-up and aftercare for patients with colon cancer. Second, the added value of Oncokompas2.0
to care will be assessed.
Methods/Design: This is a multi-centre 2 × 2 factorial randomised controlled trial with a calculated sample size of
300 patients. Patients with stage I, II, or III colon carcinoma are eligible. Patients will be randomly assigned in four
groups: (1) usual follow-up visits and aftercare provided in secondary care, (2) usual follow-up visits and aftercare
provided in secondary care with additional use of Oncokompas2.0, (3) follow-up and aftercare in primary care, and
(4) follow-up and aftercare in primary care with additional use of Oncokompas2.0. The primary outcome is quality of
life. Secondary outcomes include physical outcomes, psychosocial outcomes, number of investigations, referrals and
related communication between secondary and primary care, (time of) recurrence detection and protocol adherence,
attention to preventive care, self-management of patients, patient satisfaction, and preference of care at the end of the
trial. Data collection will be done by questionnaires and extractions from electronic medical records.
Discussion: The results of this study will provide evidence, which has been scarce to date, on prominent general
practitioner involvement in care for colon cancer patients after initial treatment. Also, it evaluates the efficacy of an
eHealth application to enhance patient empowerment.
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It is expected that in 2020 more than 17,000 cases of
colorectal cancer will be diagnosed in The Netherlands
[1, 2]. Currently, in The Netherlands after initial treat-
ment, patients are typically included in a surgeon-led
programme whose main focus is detection of recurrence
and metachronous tumours; in general, this is called
follow-up. There is evidence that intensive follow-up
programmes improve (overall) survival of patients with
colorectal cancer [3, 4]. The Dutch guideline includes
periodic visits combined with a carcinoembryonic anti-
gen (CEA) blood test, imaging of the liver, and colonos-
copy during the first five years after curative treatment
[2]. Given that this follow-up programme is convenient
to carry out, it is only a small step to hand over manage-
ment of follow-up to general practitioners (GPs), especially
since most patients have chronic co-morbid conditions
and are familiar with their GP. Furthermore, primary
health-care use is increased the first five years after colo-
rectal cancer diagnosis [5].
Patients with cancer often experience multiple phys-
ical, functional, and psychosocial problems during and
after the initial treatment phase [6]. These symptoms
can cause considerable distress. Care with the purpose
of alleviating these symptoms is called aftercare or sup-
portive care [3]. Goals of aftercare are improvement of
physical condition, finding emotional and social balance,
coping with disabilities, and restoring autonomy by in-
creasing self-efficacy and regaining confidence [7]. Cur-
rently, follow-up visits in secondary care do not always
address these aspects, and studies suggest that only a
small number of distressed patients are identified and
supported [8–10]. Recently, our research group con-
ducted a large cross-sectional survey in The Netherlands
among patients, surgeons, and GPs in which current
surgeon-led aftercare and possible future GP-led aftercare
were evaluated. Only half of the patients were satisfied
with the identification and treatment of psychosocial
problems. Moreover, three out of four surgeons stated
that, owing to their lack of time and experience, psycho-
social problems in particular possibly received not enough
attention [11]. Both the Dutch Health Council and the
Dutch Cancer Foundation suggested more care by a gen-
eralist as a solution to these problems [3, 12].
The number of cancer patients with co-morbidity is
expected to increase as a result of aging of the general
population [12, 13]. Besides giving attention to pre-
existent co-morbidity, health-care professionals should
be aware of newly developed co-morbidity after cancer
treatment. Therefore, preventive care is important for all
survivors of colorectal cancer. Moreover, disease-free sur-
vival of patients with colorectal cancer is increased in
those with higher levels of physical activity. Nevertheless,
colorectal cancer survivors have the highest percentage ofsedentary lifestyles among survivors of malignancies, and
studies suggest that professionals miss opportunities to
counsel cancer survivors—in particular, colorectal cancer
survivors—about healthy behaviours [14].
The guidelines of the Dutch National Gastrointestinal
Cancer group do not offer clear recommendations about
which health-care professional should coordinate care
after initial treatment [2]. The Dutch Cancer Society’s
Signalling Committee on Cancer emphasizes the import-
ance of primary care in cancer management [12]. GPs
with their generalist and broad view, accessibility, con-
tinuity of care, experience with chronic disease manage-
ment, and wide network of health-care providers might
therefore be the most appropriate health-care profes-
sional to provide aftercare [15]. Few studies report on
primary versus secondary care follow-up of breast and co-
lonic cancer [16–18]. These studies show no significant
difference for quality of life, recurrence rate, and anxiety.
However, GP-led cancer follow-up was more cost-effective
than hospital follow-up and this was due mainly to a dif-
ference in organisational and physician costs.
Furthermore, it would be preferable for as much of the
rehabilitation as possible to be conducted in the patients’
own environment. Besides an expanded role for GPs, a
more central role of the patient in management of his or
her own health is emphasized by the Chronic Care
Model [19]. Self-management or patient empowerment
is defined as the individual’s ability to manage symptoms,
treatment, physical and psychosocial consequences, and
lifestyle changes inherent to living with a chronic condi-
tion [20]. Evidence shows that web-based interventions for
patient empowerment can improve care for patients with
cancer [21, 22]. The aim of eHealth applications targeting
patient empowerment is to enable patients with cancer to
positively influence their treatment and rehabilitation, in
keeping with the professional execution of aftercare, by
providing them with timely insight into, for instance, their
individual state of health and their treatment stage or
needs, and by offering personal lifestyle coaching based on
their actual quality of life. An important example of these
eHealth applications is Oncokompas2.0. In Oncokompas2.0,
cancer survivors can monitor their quality of life by means
of participant-reported outcomes (PROs) (“Measure”) and
this is followed by automatically generated tailored feed-
back (“Learn”) and personalised advice on supportive care
services (“Act”) [10, 23]. It is based on the Dutch guideline
Cancer rehabilitation and Screening for the need of psy-
chosocial care [7, 24]. The above-mentioned developments
are subjects of the I CARE study because, to date, robust
research on a more prominent role for primary care and
the use of eHealth applications in the follow-up and after-
care for colon cancer patients after initial treatment is
missing and possible benefits in terms of patients’ satisfac-
tion and quality of life should be further assessed.
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efficacy of GP-led follow-up and aftercare compared
with secondary care-led follow-up and aftercare among
patients with colon cancer and to determine the added
value of the eHealth self-management application Onco-
kompas2.0. We hypothesize that GP involvement improves
aftercare and preventive care, resulting in improved
quality of life and patients’ satisfaction. Furthermore,
we hypothesize that a GP-led recurrence detection
programme (follow-up) for patients after curative treat-
ment of colon cancer leads to at least equal detection
of recurrences and subsequently an equal number of
curative recurrence resections. Finally, we hypothesize
that usage of Oncokompas2.0 facilitates patients’ self-
management and personalised access to supportive care
in cancer.
Methods/Design
This is a multi-centre 2 × 2 factorial randomised con-
trolled trial. Two randomisation procedures (at the same
moment) will be undertaken: one to create two groups for
surgeon-led—usual care (i.e., control group)—versus GP-
led follow-up and aftercare and a second randomisation
for allocation of the eHealth application Oncokompas2.0.
This factorial design results in four groups on a 1:1:1:1 ra-
tio (Fig. 1):
1. Usual follow-up visits and aftercare provided in
secondary care (surgeon-led);
2. Usual follow-up visits and aftercare provided in
secondary care (surgeon-led) with additional use of
the eHealth application Oncokompas2.0;
3. Follow-up and aftercare in primary care (GP-led);
4. Follow-up and aftercare in primary care (GP-led)
with additional use of the eHealth application
Oncokompas2.0.Fig. 1 Study flow chart. GP General practitionerRandomisation will be performed centrally at the Aca-
demic Medical Centre in Amsterdam by using block ran-
domisation to balance patient characteristics within each
group on the basis of two variables: age and tumour stage.
If a second patient of an already-participating GP is in-
cluded, this patient (and all subsequent patients) will be al-
located to the same follow-up/aftercare arm (i.e., primary
or secondary care). The chance that two patients of the
same GP will be diagnosed with colon cancer in the study
period, will be eligible for inclusion in the study, and give
informed consent is small. Nevertheless, we avoid having
two patients of the same GP receive different care (pri-
mary care-led versus secondary care-led follow-up) as this
will result in contamination. Owing to the nature of the
intervention, it is not possible to conceal the allocation
group from either participants or clinicians. However,
the primary researchers are not involved in subsequent
follow-up/aftercare appointments in any way. Recruited
patients will not be informed about other patients re-
cruited in the same trial. Similarly, no information regard-
ing trial progress will be revealed to the participating GPs
or surgeons.
The study will be conducted in eight hospitals. The
number of segmental colonic resections for cancer in
the participating centres ranges between 60 and 160 pa-
tients per centre annually.
If a patient (or GP) declines randomisation, the patient is
asked to participate in a patients’ preference group (Fig. 1).
In this arm, baseline data similar to those of the rando-
mised study arms are gathered, but the allocation is based
on the patients’ treating surgeon and patient preference.
Study population
Inclusion criteria
To be eligible to participate in this study, a subject must
meet all of the following criteria:
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defined as a tumour located 15 cm above the anal
verge by coloscopy or above the sacral promontory
as seen preoperatively;
 Stage I, II, or III carcinoma;
 Surgical treatment with curative intent;
 Qualified for routine follow-up attendance by
surgeon or oncologist according to the national
guideline;
 Patients who have temporary stoma and who
received adjuvant chemotherapy are also eligible.
Exclusion criteria
A potential subject who meets any of the following cri-
teria will be excluded from participation in this study:
 Stage IV colorectal tumours;
 Hereditary colorectal cancer (e.g., Lynch and familial
adenomatous polyposis);
 Colorectal cancer in patients with inflammatory
bowel disease;
 Rectal cancer;
 (Sub)total colectomy or proctocolectomy;
 History of second primary cancer (except basal cell
carcinoma of the skin) within the last 15 years;
 Participation in other (clinical) research, which will
affect the outcome measurements of this trial;
 Permanent open wounds after surgery or other
conditions in which specialised care is needed;
 Any other condition that warrants increased
intensity of surveillance with respect to colon cancer
follow-up;
 Not able to speak and read Dutch or English.
Inclusion procedure
Patients are asked for their informed consent postopera-
tively after the results of the pathological examination of
the resection specimen with its consequences have been
discussed with the patient. Patients will be recruited by
treating physicians at the different hospitals. The treat-
ing physician will inform patients, and written informed
consent is obtained by the research team. Participants
will be given as much time as they desire to consider
their decision.Table 1 Follow-up after colon carcinoma resection with curative int
Year 1
Office visits Every 6 months
Physical examination Only if indicated
Coloscopy of computed
tomography colonography
Within 3 months postoperatively if preoperati
the colon was not visualized completely.
If whole colon is visualized preoperatively,
coloscopy after 1 year.
The table is not applicable after endoscopic polypectomy of a T1 carcinomaIntervention
Intervention 1 (GP-led follow-up and aftercare)
Guidelines for follow-up will be according to the na-
tional guideline for colon carcinoma [2]. The follow-up
guideline is similar in both arms. GPs allocated to the
intervention arm are given written instructions on what
to do if recurrence is suspected and this mainly includes
prompt re-referral. The follow-up guidelines have been
summarized in a survival care plan especially to support
the participating GPs. This survival care plan also con-
tains information on possible physical and psychosocial
problems patients might have and subsequent interven-
tions. In case of questions regarding the information in
the letter or in the survival care plan, relevant contact
information will be supplied. The survival care plan will
also be available at the study website (see http://www.
icarestudie.nl/). Also, both surgeons and GPs are in-
formed on evidence-based recommendations concern-
ing aftercare as described in several guidelines [2, 7].
Patients randomly assigned to GP-led follow-up and
aftercare will be referred to their GP for postoperative
follow-up and aftercare according to the national guide-
line (Tables 1 and 2). An information letter provided by
the treating surgeon will be given to the GP. This letter
contains information about surgery, any complications,
disease stage, the use of chemotherapy, subsequent side
effects, and risk of recurrence of the referred patient. If
the treating surgeon or oncologist recommends an al-
tered follow-up schedule, they will give clear advice.
Intervention 2 (the use of the Oncokompas2.0)
Patients who are allocated to the eHealth application
Oncokompas2.0 (http://www.oncokompas.nl/) will receive
an account to be able to make use of the online applica-
tion. Patients who do not have the availability of internet
at home or do not possess sufficient eHealth literacy skills
will be supported in the use of Oncokompas2.0 by a trial
nurse. Oncokompas2.0 is an online self-management appli-
cation which facilitates access to supportive care in cancer
survivors. Oncokompas2.0 consists of three components:
(1) Measure, (2) Learn, and (3) Act [10].
In the “Measure” component, cancer survivors can
independently complete PROs targeting the following
quality-of-life domains: physical functioning, psychologicalent of carcinoma limited to submucosal involvement (T1N0M0)
Years 2-5
Yearly
vely 3 years after the last coloscopy, followed by coloscopies each 3–5
years depending on the number, size, and localization of polyps
Table 2 Follow-up after colon carcinoma resection with curative intent of carcinoma extending beyond the submucosa but without
distant metastasis (all stages with the exception of T1N0)
Year 1 Year 2 Year 3 Years 4-5
Office visits Every 6 months Every
6 months
Every 6 months Yearly
Physical examination Only if indicated
Carcinoembryonic antigen
monitoring
Every 3 months Every
3 months




Every 6 months Every
6 months
Yearly Yearly
Coloscopy of CT colography Within 3 months postoperatively if
preoperatively the colon was not
visualized completely.
3 years after the last coloscopy, followed by
coloscopies each 3–5 years depending on the
number, size, and
localization of polyps
If whole colon is visualized preoperatively,
coloscopy after 1 year
aComputed tomography (CT) scan is indicated if an abdominal ultrasonography is not readily interpretable (e.g., in the presence of liver steatosis), or a CT scan
can be considered in patients with a high risk of recurrence (T4N+) because of its higher sensitivity
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ential issues. Data from the “Measure” component are
processed in real time and linked to tailored feedback to
the cancer survivor in the “Learn” component. In the
“Learn” component, feedback is provided to the partici-
pant on the level of the topics (e.g., depression and fatigue)
by means of a three-color system: green (no elevated well-
being risks), orange (elevated well-being risks), and red
(seriously elevated well-being risks). Cancer survivors
receive elaborated personalised information on the out-
comes; for example, on the topic of depression, infor-
mation is provided on the symptoms of depression and
the proportion of cancer survivors who have depression.
Special attention is paid to evidence-based associations be-
tween outcomes. For example, additional feedback on the
association between depression and fatigue is provided if a
participant has an orange or a red score on depression as
well as on fatigue. The feedback in the “Learn” component
concludes with comprehensive self-care advice (tips and
tools). All this advice is tailored to the individual cancer
survivor.
In the “Act” component, survivors are provided with
personalised supportive care options on the basis of their
PRO scores and expressed preferences (e.g., guided or
unguided interventions and preference for individual
therapy versus group therapy). If a participant has ele-
vated well-being risks (orange score), the feedback in-
cludes suggestions for self-management options. If a
participant has “seriously elevated well-being risks” (red
score), the feedback includes advice to contact their own
medical specialist or GP for further medical evaluation.
Supportive care options are extracted from a national
database with those options.
Oncokompas2.0 comprises a generic module for all can-
cer survivors, targeting psychological functioning (anxiety,
depression, fear of recurrence, and cognitive functioning),
physical functioning (pain, sexuality, sleep, fatigue, bodyimage, diarrhoea, constipation, hearing, loss of appetite,
nausea/vomiting, lymph oedema, dyspnoea, and function-
ing in daily living), social functioning (social life/loneliness,
relationships, financial issues, return to work, and com-
munication with care providers), healthy lifestyle (smok-
ing, alcohol use, exercising, nutrition, weight, and stress),
and life questions. Furthermore, a tumour-specific module
for colon cancer, targeting bladder and urinary problems,
heredity, stools, ostomy, pain, and abdominal bloating, is
available for study participants of the I CARE study.
Outline of the study and data collection procedures
Approximately 3–4 weeks postoperatively, patients will
be seen at the surgical outpatient clinic. At this visit, a
clinical examination will be performed, and information
about the histology and results of the surgery will be
shared with each patient. Patients not receiving adjuvant
chemotherapy and eligible for study inclusion will be
asked for their informed consent. Also, patients who
need adjuvant chemotherapy and are eligible for study
inclusion will be asked for their informed consent. How-
ever, before final inclusion in the study, the patients will
be referred to the oncologist for chemotherapeutic treat-
ment. After completion of adjuvant chemotherapy, these
patients will be included definitively.
After a patient has given informed consent, the GP is
contacted if he or she wants to participate in the study.
If the GP participates, the patient is finally randomised.
If a patient declines randomisation (or the GP of the
patient declines randomisation), the patient is asked to
participate in a patients’ preference group and will re-
ceive surgeon-led follow-up and aftercare. Patients allo-
cated to GP-led follow-up may be referred back to the
hospital at any time during the study. Similarly, patients
in the surgeon-led groups are free to consult their GP
any time during the study. Subjects can leave the study
at any time for any reason without any consequence.
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Data will be collected in all groups in identical ways and
at identical time points. Changes in health status and
valuation over time will be measured by using the fol-
lowing questionnaires:
1. Generic and disease-specific quality-of-life
questionnaires (EORTC QLQ-C30, EORTC
QLQ-CR29, and EQ-5D-5 L) [25–27].
2. Patients’ satisfaction (consumer quality index
questionnaire) is measured [28].
3. A short list of questions concerning smoking habits,
height, weight, physical exercise, and perceived
autonomy (based partly on existing questionnaires)
[29, 30].
4. Patient activation (Patient Activation Measure
questionnaire) and perceived efficacy in patient-
physician interactions (5-item Perceived Efficacy in
Patient-Physician Interaction Questionnaire (PEPPI-5)
questionnaire) [31, 32].
5. Short questionnaire on process evaluation regarding
Oncokompas2.0.
The majority of these questionnaires will be filled out
directly after the first postoperative visit at the out-
patient clinic department and after 3, 6, 12, 24, 36, 48,
and 60 months. Extractions from the GPs’ electronic
medical record (EMR) and PROs will be used to evaluate
preventive care. We will use the EQ-5D-5 L to calculate
quality-adjusted life years. For the economic evaluation,
health-care utilisation will be measured by using the iMTA
Medical Consumption Questionnaire (iMTA MCQ) [33].
The Short-Form Health and Labour Questionnaire (SF-
HLQ) will be used to measure absenteeism from paid and
unpaid work.
GPs will be asked at the end of the study to fill out a short
questionnaire to evaluate care. Focus group interviews are
planned with patients and health-care professionals (GPs,
surgeons, and nurses involved in aftercare) to evaluate their
experiences, limitations, and recommendations.
Quality control
An independent data and safety monitoring board (DSMB)
will evaluate the progress of the trial and will examine
safety parameters at regular intervals (every 45 patients or
every 6 months). In particular, all recurrences will be
assessed to analyse whether there is a diagnostic delay
caused by the study protocol. Also, all involved physicians
will repetitively be asked by the primary researchers to re-
port any potential adverse events caused by following the
study protocol. These adverse events will be listed and dis-
cussed with the DSMB. The input of the study participants
along with a progress report of the project leader (JW) will
be supplied to the DSMB before they have a meeting. Alldeceased patients will be evaluated by the safety committee
for cause of death and possible trial-related serious adverse
effects. The DSMB committee can ask for a full report in
order to discuss a specific adverse event. The DSMB will
consist of an epidemiologist/statistician who is the chair-
man, an independent surgeon, and an independent GP.
None of these members has a conflict of interest with the
sponsor of the study. The advice of the DSMB will be sent
to the sponsor of the study. Should the project leader de-
cide not to fully implement the advice of the DSMB, the
sponsor will send the advice to the reviewing ethics com-
mittee, including a note to substantiate why (part of) the
advice of the DSMB will not be followed.Analysis
Sample size
The sample size calculation is based on the primary end-
point: quality of life. In accordance with previous stud-
ies, we consider an effect of 10 units of improvement of
the EORTC QLQ C30 to be clinically relevant [34]. To
detect an intervention effect of 10 units of change
(standard deviation of 20) in quality of life, we will need
64 participants in each group (alpha of 0.05 and power
of 80 %). As we expect some drop-out, we aim for 75
patients in each group. The total sample size is therefore
300 patients. Given the sample size calculation and the
factorial design of the study, the assumptions are made
that the effects of the two interventions are independent
and that there are no important interactions (synergy).Analysis of main study parameters
All analysis will be performed according to the intention-
to-treat principle. Crude data are presented with statistical
comparison made between randomisation groups on the
basis of chi-squared tests for binary or categorical data,
the t test or analysis of variance as appropriate for com-
paring group means, and the Kruskal-Wallis test for com-
paring medians. For continuous normally distributed data,
the analysis-of-variance test will be used. The primary ana-
lysis will be the comparison between factors, and the com-
parison between study arms will be part of a secondary,
exploratory analysis. For these purposes, univariate and
multiple linear or logistic regression analyses will be per-
formed. Quality of life will be assessed through multi-level
modelling. A two-sided P value of less than 0.05 will be
considered statistically significant. Nevertheless, in all ap-
propriate cases, 95 % confidence intervals will be given.
Changes in health status and valuation over time will
be measured by using the questionnaires mentioned
above. Next to validated questionnaires and prospective
monitoring of the trial endpoints, extractions from the
GPs’ EMR and patients’ hospital records will be used to
complete the data.
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The aims of the economic evaluation are to describe the
societal costs of patients who after an operation for
colon cancer receive follow-up at the hospital or by the
GP and to relate these costs to the clinical effects in
these groups. The time horizon of the economic evalu-
ation is up to 5 years after surgery. A societal perspective
is chosen, meaning that not only health-care costs but
also patient and lost productivity costs are taken into ac-
count. Health-care utilization will be measured by using
the iMTA MCQ at baseline and after 3, 6, 12, 24, 36, 48,
and 60 months of follow-up [33]. Health-care costs in-
clude costs of GP care, costs of psychiatric and psycho-
logical care, costs of ambulatory and inpatient hospital
care, costs of visits to allied health-care professionals
such as physical therapists and social workers, costs of
medication and examinations, and costs of home care.
The SF-HLQ will be used to measure absenteeism from
paid and unpaid work at all follow-up moments. For the
valuation of health-care utilization, standard prices pub-
lished in the Dutch costs guidelines will be used [35].
Medication use will be valued by using prices of the
Royal Dutch Society for Pharmacy [36]. Quality of life
will be measured by using the 5-level version of the
EuroQol (EQ-5D-5 L) [27]. Health states will be con-
verted to utility scores by using the Dutch tariff for the
EQ-5D-5 L. Quality-adjusted life-years will be calculated
by using linear interpolation between time points.
Costs will be discounted at 4 % and effects at 1.5 %
as recommended by the Dutch guidelines for costing
studies [29]. Missing cost and effect data will be imputed
by using multiple imputation according to the MICE
(Multiple Imputation by Chained Equations) algorithm
developed by Van Buuren et al. [37]. Costs typically have a
highly skewed distribution [38]. Therefore, bias-corrected
and accelerated bootstrapping with 5000 replications
will be used to estimate 95 % confidence intervals around
the mean difference in total societal costs between the
groups. Incremental cost-effectiveness ratios (ICERs) will
be calculated by dividing the difference in mean total costs
between the groups by the difference in mean effects be-
tween the groups. Bootstrapping will be used to estimate
the uncertainty surrounding the ICERs which will be
graphically presented on cost-effectiveness planes. Cost-
effectiveness acceptability curves will also be estimated.
Cost-effectiveness acceptability curves show the probabil-
ity that care by GPs is cost-effective in comparison with
usual care for a range of different ceiling ratios, thereby
showing decision uncertainty [39]. The iMTA MCQ
and SF-HLQ questionnaires will be sent to the partici-
pant simultaneously with the quality-of-life question-
naires (EQ-5D-5 L) to facilitate patient’s response.
Besides the information provided by the patients them-
selves by means of the methods mentioned above, theresearchers will systematically gather data directly from
hospital and GP files. This information will be used to
compare health-care usage and be correlated to compare
health-care costs. The following items will be checked
at the time intervals mentioned above: outpatient clinic
visits, GP practice visits, telephone consultations, hospital
admittances (number of days), laboratory tests, all medical
imaging, endoscopies, referrals to (other) medical special-
ist care, referrals to paramedical care, and drug prescrip-
tions. Note that health-care use in both primary and
secondary care will be evaluated for patients allocated to
any group of randomisation to create a complete survey of
health-care use.
Each single item will be stored in the case record file
created for each participant. Via this information from
health-care use, the costs used by each participant will
be determined by using standardised reference lists.
Ethics and safety
The medical ethics committee of the Academic Medical
Centre (Amsterdam, The Netherlands) has approved
the study protocol (MEC 2014_332). This study will be
conducted according to the principles of Good Clinical
Practice.
Discussion
The aims of this study are to examine the quality of care
for patients after colon cancer treatment in primary care
and to determine the effect of the use of the eHealth ap-
plication Oncokompas2.0 in these patients. To date, the
evidence on this subject has been scarce. Nevertheless,
future care for the so-called “cancer tsunami” should be
organised efficiently and in the best way for patients, in
which currently unmet physical and psychosocial needs
are better addressed. The I CARE study will provide evi-
dence regarding the question of whether GPs should
have a more prominent role in follow-up and aftercare
for patients with colon cancer after their initial treat-
ment. The randomised I CARE study not only evaluates
quality of life and patients’ satisfaction but also assesses
safety and costs during a 5-year follow-up time.
Trial status
At the time of submission, the study protocol was ap-
proved by our medical ethics committee and registered
in the Dutch Trial Register. Recruitment of participants
started in April 2015.
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